Geron Corp (GERN.OQ) Key Developments | Reuters.com
Edition:
United States

Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

2.59USD
24 Jun 2016
Change (% chg)

$-0.16 (-5.82%)
Prev Close
$2.75
Open
$2.63
Day's High
$2.69
Day's Low
$2.57
Volume
679,586
Avg. Vol
474,077
52-wk High
$5.25
52-wk Low
$2.31

Latest Key Developments (Source: Significant Developments)

Geron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis
Wednesday, 16 Sep 2015 07:30am EDT 

Geron Corporation:Announces that it has initiated a new site for its ongoing Phase 1/2a TT-034 trial at the Methodist Health System Clinical Research Institute in Dallas, Texas.Says the site has commenced pre-screening hepatitis C patients and is led by principal investigator Parvez Mantry, a gastroenterologist and hepatologist.  Full Article

Geron Corp announces global strategic collaboration with Janssen to Develop and Commercialize Imetelstat
Thursday, 13 Nov 2014 04:15pm EST 

Geron Corp:Says it has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses.Geron will receive an initial payment of $35 mln due after the applicable waiting periods under the Hart-Scott Rodino Act.And it is eligible to receive additional payments up to a potential total of $900 mln for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales.  Full Article

BRIEF-Geron Corp reports Q1 loss per share $0.06

* Geron corporation reports first quarter 2016 financial results and recent events